Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03103919 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
A Phase 4 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03103919 is a Phase 4 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 40 participants.
The verdict
NCT03103919, a Phase 4 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard clinical practice.
Interventions
- DRUG Rotigotine
- DEVICE Kinesia-ONE™
- DEVICE Kinesia-360™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-03-16 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03103919
The ClinicalTrials.gov registry entry for NCT03103919 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rotigotine is the first listed.
NCT03103919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03103919 about?
NCT03103919 is a clinical study titled "Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management". Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard clinical practice.
What is the current status of trial NCT03103919?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-03-16. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT03103919?
The interventions under investigation include: Rotigotine (DRUG), Kinesia-ONE™ (DEVICE), Kinesia-360™ (DEVICE).
Who is sponsoring clinical trial NCT03103919?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.